MDES and Huawei Cloud Announced Joint Initiative to Accelerate Thailand's Agenda to Become the AI Hub in ASEAN
Seizing AI Opportunities to Accelerate Thailand's AI Hub Agenda
Professor Wisit Wisitsora-At, Permanent Secretary of MDES, stated: "Thailand is committed to becoming the AI hub in ASEAN. With our 'Cloud First' policy, AI strategy, infrastructure investment, and a thriving ecosystem, Thailand is transitioning from a technology user to a competency builder, allowing Thailand's own innovations to benefit the world." Professor Wisit Wisitsora-At acknowledged Huawei Cloud's continuous efforts in promoting innovation and digital transformation.
Sunny Shang, President of Huawei Cloud Asia Pacific, emphasized: "In the AI era, intelligence brings us immense opportunities. In Thailand, Huawei Cloud is not only a technology provider but also a co-builder of the digital ecosystem. We will work with local customers and partners to accelerate Thailand's intelligent transformation through four key initiatives: deep local engagement, technology leadership, experience sharing, and ecosystem co-building."
After seven years of deep local engagement, Huawei Cloud has served more than 1,000 customers and developed more than 500 partners in Thailand. Mainstream local carriers, more than 80% of top financial institutions, and over 60% of top retailers in Thailand have chosen Huawei Cloud.
Forging an AI-Native Cloud to Embrace Intelligence
William Dong, President of Huawei Cloud Marketing, unveiled four solutions at the summit, which focus on a strong AI foundation, intelligent application development, intelligent data management, and all-scenario cloud deployment. He emphasized that AI has become the most influential general-purpose technology in the industry. Huawei Cloud is actively embracing AI and has made a full transition from "Cloud-Native" to "AI-Native" in two aspects: "Cloud for AI" and "AI for Cloud". "Cloud for AI" accelerates the implementation of AI strategies by systematically innovating the technology stack and building the best cloud platform. "AI for Cloud" means reshaping Huawei Cloud services with AI to make them intelligent.
Strong AI foundation: Huawei Cloud AI Cloud Service enables model training jobs to run uninterrupted for up to 40 days, among other large-scale training needs. More than 160 mainstream foundation models are available for use and are now employed by over 1,000 AI enterprises. For scenario-specific demands, Pangu models provide tailored solutions and support, already proven viable in scenarios such as railway track inspection, steel blast furnace temperature prediction, and weather forecast.
Intelligent application development: CodeArts, Huawei Cloud's software development pipeline, delivers intelligence in code generation, review, and testing, improving the end-to-end R&D efficiency by 30%. The Flexus LLM solution provides three capabilities: Dify HA edition, local knowledge base construction, and scenario-specific application development, facilitating small and medium-sized enterprises to develop AI applications in one stop.
Intelligent data management: DataArts, Huawei Cloud's data governance pipeline, has been fully upgraded to serve as an AI-oriented, knowledge-centric data foundation. GaussDB, the distributed cloud database, outperforms the industry benchmark twice with its transparent multi-write technology across multiple nodes. Its high availability slashes impact on service with fast fault recovery.
All-scenario cloud deployment: Huawei Cloud Stack provides a hybrid cloud for large AI models, allowing enterprises to build their own models in one stop. CloudDC, the solution for migrating data centers to the cloud, provides deterministic operations, cloud data center, and full-stack AI for different needs.
The event gave a vivid demonstration of how AI unlocks possibilities in lives and production, where a humanoid robot completed complex tasks in collaboration with a human wearing an intelligent bionic hand.
Tech for Good: Innovation for Sustainable Development
Cloud and AI technologies not only boost production efficiency but also bring a positive impact on human life, natural environment, and sustainable development. Aka Dai, Director of Huawei Cloud Marketing, illustrated Huawei's "Cloud for Good" initiative with the company's success stories in accelerating Thailand's digital journey. For example, the paperless solution jointly developed by Huawei Cloud and Codium is expected to reduce paper consumption by 18 to 25 million pages annually for over 200 government departments and 300 enterprises, equivalent to saving 2,000 to 3,000 trees and reducing carbon emissions by 30 to 50 tons. Now, Huawei Cloud is strengthening local partnerships in nature conservation, smart agriculture, inclusive finance, energy conservation, emission reduction, and talent cultivation, all for supercharging Thailand's digital transformation.
At the summit, Huawei Cloud and Chulalongkorn University jointly launched the "Cloud and AI Pioneer Initiative", which aims to cultivate 30,000 talented people in the cloud and AI fields through diversified measures such as developing cloud and AI courses, organizing developer competitions, and implementing developer programs. By the end of 2025, Huawei Cloud is projected to cultivate more than 20,000 cloud and AI developers in Thailand, an effort for building a thriving local talent ecosystem.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/mdes-and-huawei-cloud-announced-joint-initiative-to-accelerate-thailands-agenda-to-become-the-ai-hub-in-asean-302469244.html
SOURCE Huawei Cloud Thailand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Global Industrial Enzyme Markets: Innovation, Impact, and Growth
"The global industrial enzyme market is experiencing rapid growth, driven by advances in biotechnology and increasing demand across sectors like food, biofuels, and textiles. These powerful biocatalysts are revolutionizing industrial processes with greater efficiency and sustainability." BOSTON, July 7, 2025 /PRNewswire/ -- According to the latest study, the demand for Global Markets for Enzymes in Industrial Applications is projected to grow from $7.9 billion in 2024 to $10.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2024 to 2029. This report explores the current and projected market potential of industrial enzymes across various industries, offering insights into key market drivers, challenges, and opportunities, as well as the regulatory landscape. It includes forecasts through 2029, segmented by application, source, and region, along with a competitive analysis and product overview. The factors driving the market include: New Application Areas: New application areas for industrial enzymes are emerging in sectors like pharmaceuticals, cosmetics, and bioplastics, expanding their market potential. These innovations drive sustainable solutions and open up diverse revenue streams across industries. Growing Demand for Food Enzymes: The demand for food enzymes is rising rapidly due to their role in enhancing food quality, shelf life, and production efficiency. This growth is fueled by consumer preference for processed, nutritious, and clean-label food products. Request a Sample Copy of the Global Markets for Enzymes in Industrial Applications Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $7.4 billion Market size forecast $10.8 billion Growth rate CAGR of 6.5% for the forecast period of 2024-2029 Segments covered Type, Application, Source, Region Regions covered North America, Europe, Asia-Pacific, Rest of the World Countries covered U.S., Canada, Mexico, China, Japan, India, South Korea, Australia, Germany, France, Italy, Spain, U.K. Market drivers • New Application Areas • Growing Demand for Food Enzymes Interesting facts: Advances in enzyme design now leverage machine learning to enhance enzyme engineering. Enzyme applications are expanding beyond food and beverages into industries like biofuels, cosmetics, pharmaceuticals, and nutraceuticals. The report addresses the following questions: What is the projected market size and growth rate?The industrial enzyme market is projected to grow from $7.4 billion in 2023 to $10.8 billion by the end of 2029 at a CAGR of 6.5% during the forecast period. What are the factors driving the growth of the market?The market's growth is driven by the increasing demand for enzymes in the food and beverage sector and expanding application areas of enzymes. What market segments are covered in the report?The market is segmented by type, application, source, and region. Which type of industrial enzyme will be dominant through 2029?The carbohydrases segment will dominate the market through 2029. Which region has the highest market share?North America holds the highest market share. Market leaders include: AB ENZYMES ADM ADVANCED ENZYME TECHNOLOGIES AJINOMOTO CO. INC. AMANO ENZYME INC. AUMGENE BIOSCIENCES BASF BIOCATALYSTS CARGILL INC. CREATIVE ENZYMES DSM-FIRMENICH ENZYME DEVELOPMENT CORP. INTERNATIONAL FLAVORS & FRAGRANCES INC. KERRY GROUP PLC NOVOZYMES A/S Related reports: 2024 Protein Synthesis Research Review: The 2024 Protein Synthesis Research Review highlights the latest breakthroughs in genetic translation, synthetic biology, and drug development. It showcases innovative technologies and research shaping the future of protein engineering and biomedical applications. Commercial Amino Acids: Commercial amino acids are essential building blocks used across industries such as food, pharmaceuticals, and animal nutrition. Their growing demand is driven by health trends, dietary supplements, and advances in biomanufacturing. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC
Yahoo
10 hours ago
- Yahoo
The Inner Circle acknowledges, Jeremiah L. Jones, CEO as an Inner Circle Lifetime member
ALEXANDRIA, Va., July 7, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Jeremiah L. Jones, CEO is acknowledged as an Inner Circle Lifetime for his contributions to Data Access and Public Service Strategy. Jeremiah L. Jones has built an exceptional career at the intersection of data accessibility, national security, and executive leadership. With more than two decades of experience supporting a range of U.S. agencies, Mr. Jones is widely regarded as a versatile and strategic leader—often describing himself as a "Swiss Army knife" for his ability to bridge complex systems, policies, and human needs. As Chief Executive Officer, Mr. Jones spearheads initiatives focused on inclusive data access for visually impaired users, AI-powered remediation technologies, and enterprise-level negotiations for international data solutions. His work serves a critical function across multiple sectors, transforming how government entities interact with information, improve equity, and streamline decision-making. Mr. Jones earned his MBA from Virginia Tech in 2011, a master's degree in National Security from the Naval War College in 2016, and completed senior executive studies at Harvard University. These academic credentials support his deep understanding of policy, governance, and innovation. Over his 20+ year career, Mr. Jones has achieved a remarkable 95% employee retention rate and reversed an $8 million revenue shortfall, guiding it into profitability. In prior roles, he managed a $12–13 billion real estate portfolio and uncovered vital distinctions between political influence and civil service integrity—insights that now inform his work in both public and private sectors. Mr. Jones is the recipient of the Chairman of the Joint Chiefs of Staff Award and credits his professional development to a series of impactful mentors, including a Navy Secretary's speechwriter and a respected admiral who instilled the principle of humility in leadership. In addition to his executive work, Mr. Jones is a global traveler and an avid cook who specializes in Southwest Asian cuisine, including Indian and Thai-inspired vegan dishes. Looking ahead, he plans to resurrect his own dormant company, applying his wealth of knowledge to new frontiers in data accessibility, technology, and public service reform. Guided by discipline, mentorship, and a commitment to progress, Jeremiah L. Jones continues to lead with purpose and precision on the world stage. Contact: Katherine Green, 516-825-5634, editorialteam@ View original content to download multimedia: SOURCE The Inner Circle Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
12 hours ago
- Yahoo
mRNA Sequencing Market Size to Hit USD 4.02 billion by 2031, Growing at 13.6% CAGR, Benefits from Surging Prevalence of Cancer
NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global mRNA sequencing market is observing significant growth owing to the increasing prevalence of cancer and rising demand for rare disease diagnostic tools. The mRNA sequencing market is expected to reach US$4.02 billion by 2031 from US$1.67 billion in 2024; it is expected to record a CAGR of 13.6% during the forecast period. mRNA sequencing is a technique used to analyze the complete set of mRNA molecules (transcriptome) within a cell or tissue. It provides a complete view of gene expression, including the identification of known and novel transcript isoforms, gene fusions, and allele-specific expression. With its high sensitivity and precision in quantifying gene expression, mRNA sequencing serves as a valuable resource for investigating various biological processes and disease conditions. The mRNA sequencing market analysis focuses on an array of products (instruments, consumables, etc.) and services required in various types of sequencing methods, which are expected to contribute to its strength in the coming years. The report runs an in-depth analysis of market trends, key players, and future opportunities. To explore the valuable insights in the mRNA Sequencing Market report, you can easily download a sample PDF of the report - Overview of Report Findings Increasing Prevalence of Cancer: As per the International Agency for Research on Cancer (IARC), there were ~20 million new cancer cases in 2022. By 2050, this number is predicted to increase to over 35 million new cases. Lung cancer is the most commonly occurring cancer worldwide, with 2.5 million new cases that account for 12.4% of the total new cases. Breast cancer in females ranked second (2.3 million cases, 11.6%), followed by colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). An upsurge in cancer cases has led to the higher utilization of mRNA sequencing for disease diagnosis, biomarker discovery, and therapeutic development applications. RNA sequencing allows researchers to simultaneously quantify the expression levels of thousands of genes, offering a comprehensive view of the transcriptome in both cancerous and healthy tissues. This aids in tracing the genes that are expressed differently and identifying molecular signatures linked to various cancer types, subtypes, and progression stages. By examining changes in the transcriptome, RNA sequencing assists in finding biomarkers for cancer diagnosis, prognosis, and treatment response. It also enables the detection of molecular targets for precision therapies, thus aiding in the creation of targeted treatments. For Detailed mRNA Sequencing Market Insights, Visit: Surging demand for Rare Disease Diagnostic Tools: According to the Rare Disease International alliance, more than 300 million people in the world suffer from a rare disease, and over 6,000 rare disease cases were identified as of 2023. 72% of these rare conditions are genetic. Therefore, there is a huge burden of healthcare costs associated with the treatment of rare diseases—the cost is approximately 10 times higher than the cost incurred by other diseases. For example, in the US, the cost of 373 rare diseases accounts for US$ 2.2 trillion annually. Based on estimates, the healthcare cost for all known rare diseases may be in the range of US$ 7.2–8.6 trillion annually. Thus, rare diseases associated with difficulties and delays in diagnosis, lack of treatment availability, development of new treatment, and a favorable regulatory framework and accessibility would result in the development of innovative mRNA sequencing technologies. mRNA sequencing is a powerful tool for rare disease diagnosis and research, offering insights into gene expression, alternative splicing, and the effects of mutation on gene function. Ambry Genetics' ExomeReveal test is multiomic exome sequencing, which aims to enhance rare disease detection compared to traditional DNA-based methods. This test combines Ambry's RNA analysis expertise from its hereditary cancer testing platform with its ExomeNext exome sequencing test to improve diagnostic yield for rare diseases. Geographical Insights: In 2024, North America led the market with a substantial revenue share, followed by Europe and APAC. Asia Pacific is expected to register the highest CAGR during the forecast period. Stay Updated on The Latest mRNA Sequencing Market Trends: Market Segmentation Based on type, the mRNA sequencing market is bifurcated into products and services. The products segment held a larger share of the market in 2024. In terms of method, the mRNA sequencing market is segmented into first-generation sequencing, next-generation sequencing, and third-generation sequencing. The next-generation sequencing segment held the largest share of the market in 2024. In terms of end user, the mRNA sequencing market is segmented into healthcare facilities, pharmaceutical and biotechnology companies, clinical research organizations, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2024. The mRNA sequencing market is segmented into five major regions: North America, Europe, APAC, the Middle East and Africa, and South and Central America. Competitive Strategy and Development Key Players: A few major companies operating in the mRNA sequencing market include Takara Bio Inc.; Illumina, Inc.; QIAGEN; F. Hoffmann-La Roche Ltd; Quantabio; Zymo Research Corporation; baseclick GmbH; Paragon Genomics, Inc.; Yeasen Biotechnology (Shanghai) Co., Ltd.; Novogene Co, Ltd; and Norgen Biotek Corp. Trending Topics: Advancements in mRNA sequencing, AI in next-generation sequencing, mRNA vaccines, innovative consumables used for mRNA sequencing, etc. Purchase Premium Copy of Global mRNA Sequencing Market Size and Growth Report (2021-2031) at: Global Headlines on mRNA Sequencing Roche unveiled its proprietary, breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation sequencing. Foundation Medicine, Inc., announced the US launch of FoundationOneRNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes. Lexogen unveiled the LUTHOR High-Definition Single Cell 3' mRNA-Seq Kit. The kit can detect a single gene copy within a cell, enabling researchers to get visuals of each cell's complete transcriptome, capturing 95% of expressed genes with high magnification. PacBio announced the expansion of Multiplexed Arrays Sequencing (MAS-Seq) for new assays. This assay is based on the successful "MAS-Seq" concatenation technology that enables cost-effective single-cell isoform sequencing. For More latest Life Sciences Research Reports & Industry Analysis - Conclusion The rising demand for diagnostic tools for rare diseases and cancer therapeutics propels the growth of mRNA sequencing market. Studies have shown that incorporating mRNA sequencing can increase the diagnostic rate for rare diseases by 7–36% compared to the diagnoses based on DNA sequencing alone. According to the study "Analysis of RNAseq from 4,400 individuals in the 100,000 Genomes Project identifies new potential diagnoses," published in the European Society of Human Genetics in June 2023, analysis from the 100,000 Genomes Project suggests that over 20% of individuals that remain undiagnosed under genome or exome sequencing may receive a diagnosis through mRNA sequencing. Thus, significant contributions of mRNA sequencing to disease diagnostics, drug discovery pipelines, and personalized medicine are adding to its popularity. The use of this sequencing technology is also on the rise in cancer research and tests for the diagnosis of uncommon genetic abnormalities. There has been an upsurge in the adoption of new high-throughput NGS technologies—ThermoFisher's Ion Torrent and Illumina's NovaSeq—in various applications. The report from The Insight Partners provides several stakeholders—including component providers, system technology integrators, and system manufacturers—with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. Trending Related Reports: About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us:Contact Person: Ankit MathurE-mail: +1-646-491-9876Site: Logo: View original content to download multimedia: SOURCE The Insight Partners Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
